The Biden administration within days is expected to select the next batch of drugs that will be subject to Medicare price negotiations — a process that this time could include Novo Nordisk's blockbusters Ozempic and Wegovy. The political appeal of bringing down the price of the wildly popular drugs and other medicines for seniors could outweigh deep misgivings in Republican circles about one of Democrats' most significant health policy achievements.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
